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Take home message 
Conventional microbiological culture diagnosis of ventilator-acquired 
pneumonia can take 2-3 days. We present a 16S PCR based assay that can allow 
rapid identification of patients with and without VAP. 
 
140 character summary 
16S PCR assay can rapidly identify patients with ventilator-acquired pneumonia, 




Ventilator-acquired pneumonia (VAP) remains a challenge to intensive care 
units, with secure diagnosis relying on microbiological cultures that take up to 
72 hours to result.  We sought to derive and validate a novel, real-time 16S rRNA 
gene polymerase chain reaction (PCR) for rapid exclusion of VAP.   
Bronchoalveolar lavage (BAL) was obtained from two independent cohorts of 
patients with suspected VAP. Patients were recruited in a two-centre derivation 
cohort and a 12-centre confirmation cohort.  Confirmed VAP was defined as 
growth of >104 colony forming units/ml on semi-quantitative culture and 
compared to a 16S PCR assay.  Samples were tested from 67 patients in the 
derivation cohort, 10 (15%) of whom had confirmed VAP. Using cycles to cross 
threshold (Ct) values as the result of the 16S PCR test, the area under ROC curve 
(AUROC) was 0.94 (95% CI 0.86-1.0 p<0.0001).   Samples from 92 patients were 
available from the confirmation cohort, 26 (28%) of whom had confirmed VAP.  
The AUROC for Ct in this cohort was 0.89 (95% CI 0.83-0.95 p<0.0001).  This 
study has derived and assessed the diagnostic accuracy of a novel application for 
16S PCR.   This suggests that 16S PCR in BAL could be used as a rapid test in 





Ventilator-acquired pneumonia (VAP) remains a significant problem in intensive 
care units (ICU) 1, and despite reductions in reported VAP rates antibiotic use 
remains high 2. The commonest indication for antibiotic use remains suspected 
respiratory infections 3.  VAP is associated with a significant morbidity and 
mortality 1 especially when antibiotics are delayed or are inadequate 4.  
However, due to the various conditions that can mimic VAP, commonly only 30% 
of those suspected of having VAP subsequently have this diagnosis confirmed 4.  
The delays in obtaining results from conventional microbiological cultures lead 
to empiric use of broad-spectrum antibiotics of which a significant proportion is 
later deemed unnecessary.    The excessive use of antibiotics is associated with 
increased anti-microbial resistance 5 and mortality 6.  
The ubiquitous presence of a 16S ribosomal RNA gene in bacteria offers the 
possibility of detecting a wide range of bacteria in a single polymerase chain 
reaction (PCR) 7. Amplification of the 16S rRNA gene in a PCR assay results in 
amplification of all bacteria in a sample. Therefore, this offers potential as a 
screening test for suspected VAP. This aim of this study was to derive and 




Samples from two previously described 8,9 cohorts of adult patients with 
clinically suspected VAP recruited from UK ICUs formed the derivation 8 and 
confirmation 9 cohorts respectively. Briefly, patients were recruited if they met 
criteria for suspected VAP, namely new or worsening chest X-ray changes 
following at least 48 hours of ventilation, accompanied by two or more of: 
temperature >38°C; white cell count  >11x109/L; or mucopurulent sputum.  In 
the derivation cohort patients were excluded if they had received new antibiotics 
within the 3 days prior to recruitment8, no such exclusion was applied to the 
confirmation cohort9.  Patients underwent protocolised bronchoscopic 
bronchoalveolar lavage (BAL) 8,9 and an aliquot of BAL fluid was processed using 
a semi-quantitative culture method. This culture was used as our reference 
diagnostic standard, with growth at >104 colony forming units/ml lavage being 
defined as ‘VAP positive’ and growth <104 CFU/ml as ‘VAP negative’, these cut-
offs being in line with established standards 1,4.      
 
Full details of sample processing are described in the supplemental section.  
Briefly, the fraction of lavage not used for conventional culture was centrifuged 
to produce a cell free supernatant, followed by nucleic acid extraction. The 16S 
PCR assays are described below, assay 1 and 2 were conducted in geographically 
separate laboratories.    
 
Real-time 16S PCR assay 1 
The primer and probe sequences targeting the16S rRNA gene have been 
described previously10. The probe contained a FAM label on the 5’ end with a 
Black Hole Quencher 1 (BHQ1) on the 3’ end. Primers and probe were 
synthesised by Eurogentec (Liège, Belgium). The final 16S PCR reaction mix 
contained 1.25U HotStarTaq polymerase and 1x reaction buffer (Qiagen, 
Manchester, UK), 4 µM MgCl2, 0.2mM dNTP, 0.25µM primer 27-F, 0.75µM primer 
16S 1RR-B, 0.3µM probe 514-S, nuclease-free water (Promega, Southampton, 
UK) and 10µl nucleic acid extract to a final volume of 25µl. Real-time PCR was 
carried out on the ABI 7500 instrument (Applied Biosystems, Life Technologies 
Ltd, Paisley, UK). This assay was used for samples from the derivation cohort, to 
establish proof-in-principle of the diagnostic utility of this approach, and was 
also used for samples from the confirmation cohort. 
 
Real-time 16S PCR assay 2 
The primer and hybridisation probe sequences targeting the 16S rRNA gene 
have been described previously S1. The hybridisation probe contained a FAM 
label on the 5’ end with a Black Hole Quencher 1 (BHQ1) on the 3’ end. Primers 
and hybridisation probe were synthesised by Sigma Genosys (Sigma-Aldrich, 
Ebersberg, Germany).  
The final 16S PCR reaction mix contained 1X Platinum® UDG Mastermix (Life 
Sciences, Paisley, UK), 0.2 µM bovine serum albumin (Sigma, Dorset, UK), a total 
of 4 mmol/L MgCl2, 0.4 µM forward and reverse primers, 0.1 µM hybridisation 
probe, nuclease free water (Promega, Southampton, UK) and 2 µl of target 
template for a final reaction volume of 10 µl. Real-time qPCR was carried out on 
a Light Cycler 480 instrument (Roche, Indianapolis, IN, USA).   This assay was 
used on samples from the confirmation cohort only. 
 
For the purposes of analysis, the metric was cycles to cross threshold (Ct) as a 
measure of 16s rRNA gene load and hence bacterial burden.  A higher bacterial 
load will result in a lower time to cross threshold, i.e. a lower Ct value.  Details of 
statistical analyses used can be found in the supplemental methods section.  Both 
studies had approvals from relevant research ethics committees, full details are 




In the derivation cohort, samples from 67 patients were available, of whom 10 
(15%) had ‘microbiologically confirmed VAP’. In the  ‘confirmation’ cohort 
samples from 92 patients were available for analysis; 26 (28%) met the culture 
criteria for ‘microbiologically confirmed VAP’. The demographic details and 
organisms cultured are shown in the supplemental section (tables S1 and S2).  
 
16S PCR assay 1 demonstrated that patients with confirmed VAP had a higher 
bacterial burden, as signified by a lower Ct value, than those without VAP (figure 
1A).  When evaluated for diagnostic ability by ROC curve, assay 1 demonstrated 
excellent diagnostic ability (see table 1 and figure S1A) with an AUROC of 0.94 
(95% confidence interval 0.86-1.00) and sensitivity of 100% and specificity 72% 
at the most optimal cut-off. 
 
In the confirmation cohort, patients with confirmed VAP had significantly lower 
16S Ct values (figure 1B), and a similar diagnostic performance was 
demonstrated (table 1 and figure S1B), with sensitivity of 100% and specificity 
of 67% at the most optimal cut-off.  The difference between the AUROC of the 
cohorts was not significant (p=0.56). 
 
Samples from the confirmation cohort were also tested using 16S assay 2.  As 
seen in figure 1C, although the absolute Ct values differed between the two 
assays, the same relationship between VAP and non-VAP samples was observed. 
ROC analysis (table 1 and figure S1C) demonstrated good diagnostic ability (AUC 
0.84 95% CI 0.75-0.94) with sensitivity 89%, specificity 80% at the optimal cut-
off.  Although the point estimates of AUROC were higher for assay 1, the 
difference did not achieve significance (p=0.4). However if the assays are 
compared at maximal sensitivity (100%), the specificity of assay 1 is significantly 
higher (table 1).  Using the Youden index to define optimal Ct value cut-offs on 
the ROC curve, a ‘positive’ result for 16S would be a value below this cut off 
(indicating high bacterial load) and a ‘negative’ result would be a value above 
this cut off (indicating low bacterial load). 
 
In the derivation cohort, 35 (52%) of patients were receiving antibiotics on the 
day of recruitment. In the confirmation cohort, 69 (75%) were receiving 
antibiotics and 14 (15%) had undergone change of antibiotics within the past 3 
days.  Receipt of antibiotics and recent change in antibiotics were not associated 
with changes in 16S Ct values (see supplemental results and table S3). 
 
Figure S2 shows the relationship between Ct values for the two 16S assays, 
demonstrating a non-linear association. 
 
Discussion 
To our knowledge, this is the first report of the use of real-time 16S PCR for 
diagnosing VAP. Although 16S rRNA gene sequencing has been used to explore 
the microbiome of ventilated patients, data on its diagnostic potential have been 
absent.   In deriving and confirming a test, with a high agreement in test 
performance between the two cohorts, we demonstrate clear potential for the 
clinical utility of this test.  Turn-around-time is 4-6 hours; therefore, this test 
could impact on antibiotic use, which may otherwise only be rationalised 
following the results of conventional cultures at 48-72 hours.  
 
This study has a number of strengths.  Firstly, we were able to perform 
derivation and confirmation in two distinct cohorts, with confirmation in a 
cohort recruited from a diverse group of 12 intensive care units.  The results are 
therefore likely to be widely applicable; indeed, the microbiological spectrum 
found is similar to reports from other countries 4.  Secondly, by using consistent 
diagnostic procedures within each cohort, we avoided some of the problems 
which occur with the diagnosis of VAP 1,4.    Our rate of microbiologically 
confirmed VAP in both cohorts (23%) is at the lower end of the reported range4 
but not out of keeping with other reports and we believe this may, in part, reflect 
the use of highly standardised BAL protocols.   
 
A disadvantage of this study is that samples were obtained bronchoscopically, 
requiring resource and exposing patients to a small but definite risk, and the 
applicability of this test to other sample types cannot be inferred.   The assays we 
describe here are also limited to bacterial detection.  The differences between 
the two assays tested, and the use of stored samples, highlight the need for 
external prospective validation before this measure could be implemented in 
routine clinical practice. Further refinements of assays may also improve 
diagnostic performance.  The reference standard, of growth of organisms on 
conventional culture, remains imperfect, and indeed may well be influenced by 
inter-current antibiotics generally, and recent changes in antibiotics 
specifically11.   However this remains the established standard4, and is used 
routinely for clinical decision-making.   As such, the 16S assay described here can 
predict the results of a clinically relevant test, but within 6 hours rather than the 
48-72 hours taken for the conventional cultures. 
 
 
In conclusion, we have derived and confirmed the diagnostic utility of a rapid 
laboratory test for VAP in a multicentre setting. We propose that this test has the 
potential to permit rapid decisions to direct antimicrobial therapy in patients 
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Table 1: Diagnostic performance of the two 16S assays 
(ROC curves displayed in figure S1).  AUC- Area under curve. Ct –Cycles to 
crossing threshold. As avoiding false-negative results is important in rapid tests 






Figure 1:  Real-time 16S PCR results as expressed by cycles to cross 
threshold (Ct) for samples from patients.   
Panel A. Ct values from assay 1 amongst derivation cohort patients with and 
without confirmed VAP.  N=67, 57 non-VAP and 10 VAP,  error bars show 
median and inter-quartile range. **** p<0.0001 by Mann-Whitney U test. 
Panel B.  Ct values from assay 1 amongst confirmation cohort patients with and 
without confirmed VAP.  N=92, 66 non-VAP and 26 VAP,  error bars show 
median and inter-quartile range. **** p<0.0001 by Mann-Whitney U test.  
Panel C.  Ct values from assay 2 amongst confirmation cohort patients with and 
without confirmed VAP.  N=92, 66 non-VAP and 26 VAP,  error bars show 
median and inter-quartile range. **** p<0.0001 by Mann-Whitney U test.  
 
Supplemental methods – Marked up version 
 
Semi-quantitative culture of BAL fluid 
After thorough mixing, 10l of whole BAL fluid was inoculated and evenly spread 
onto solid culture media and incubated for 40-48 hours. The resulting number of 
colonies of bacterial pathogens was counted, with fewer than 10 taken to 
indicate <103 colony-forming units (CFU) per mL, 10-100 colonies indicating 
103-104 CFU/mL, and greater than 100 colonies indicating >104 CFU/mL. 
Confirmed VAP was defined as growth of bacteria at >104 CFU/ml 1,4. 
 
Sample processing 
BAL fluid was prepared as described previously 8,9 with the cell-free supernatant 
being stored at -80°C. BAL fluid from the derivation cohort underwent nucleic 
acid extraction using the DNeasy Blood and Tissue kit (Qiagen, Manchester, UK) 
with a pre-treatment protocol for Gram positive bacteria according to the 
manufacturer’s instructions. Nucleic acid extraction on samples from the 
validation cohort was completed using MagNA pure 96 DNA and viral NA small 
volume kit (Roche, Indianapolis, IN, USA), by different staff, in a separate 
laboratory.  Negative control samples comprising sterile saline underwent 





Non-normal data are presented as median and inter-quartile range, and analysed 
by Mann-Whitney U- test.  The diagnostic performance of the 16S assays, 
expressed as cycle number to cross threshold (Ct) was analysed by plotting 
Receiver Operator Characteristic (ROC) curves, with optimum cut-off defined by 
the Youden index (the cut off which produces the largest sum of sensitivity and 
specificity)S2.  Differences between areas under ROC curves were analysed by the 
methods of Hanley and McNeilS3,S4.  P<0.05 was taken to indicate statistical 
significance. Analysis was conducted using Prism (v5f for Mac, Graphpad, 
Carlsbad, CA, USA). 
 
Ethical permissions 
All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national 
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Research Ethics Committee (REC) (LREC/2002/8/19) and NRES North East REC 
(11/NE/0242) and Scotland A REC (11/SS/0089), respectively, with informed 










Characteristic Derivation cohort Validation 
N= 67 92 
Mean Age (range) years 59 (26-87) 60 (18-87) 
% male 65% 71% 
Median (IQR) APACHE 
II Score on admission 
21 (16-26) 20 (15-23) 
% Surgical admission 50% 41% 
Median (IQR) ICU 
length of stay 
23 (15-30) 19 (12-35) 
% ICU mortality 28% 28% 
% Hospital mortality 33% 37% 
% Receiving antibiotic 
at time of lavage 
52% 75% 
% undergoing change 
in antibiotic therapy 
within 3 days of 
enrolment 
0% 15% 






Type of organism Derivation Validation 
Enterobacteriaceae  4 9 














Table S2: Bacteria grown at >104 CFU/ml in the derivation and validation 
cohorts.  Two patients in the validation cohort grew more than one organism 
above the threshold. 
 
 
Influence of antibiotics on results of the 16s assay 
 
In the derivation cohort, 35 (52%) of patients were receiving antibiotics on the 
day of recruitment, and none had experienced a change in antibiotics in the 
preceding three days. In the validation cohort, 69 (75%) of patients were 
receiving antibiotics on the day of enrolment.   As can be seen in table S3 below, 
there were no significant differences in Ct values between patients receiving 
antibiotics, and those not receiving antibiotics, in either assay.  Recent change in 
antibiotics is more likely to create ‘false negatives’ on conventional cultures11, 
and (15%) of validation cohort patients had a change of antibiotics in the 
preceding three days.  Again we found no difference in Ct values between these 






























































Table S3.  Ct values for patients by antibiotic status at time of study recruitment. 
Values shown as median (interquartile range), p value from Mann-Whitney U 
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Figure S1: ROC curves for real-time 16S assays.  Details of test performance 
are shown in table 1 of the main manuscript. 
Panel A. ROC from assay 1 amongst derivation cohort patients with and without 
confirmed VAP.  
Panel B. ROC from assay 1 amongst validation cohort patients with and without 
confirmed VAP.   
Panel C.  ROC from assay 2 amongst validation cohort patients with and without 











Figure S2: Relationship between results from real-time 16S PCR assays 1 
and 2 on the validation cohort samples.  The regression line describes a non-
linear function (y=28.96+3.38xX+0.06xX2), r2=0.91, results from n=92 samples. 
 
 
 
 
 
  
 
 
 
